Thursday, December 11, 2014 8:26:40 AM
India Hep C trial data was great…Yes some are skeptical of India trials
Well Aemd is now enrolling for the Hep C trial in Houston per FDA IDE authorization
Who is Davita? They are a $15 BILLION dollar company with over 1 BILLION CASH in the bank & a company called Berkshire Hathaway owns about 17% of eva http://finance.yahoo.com/q?s=DVA
So if IDE Houston data is great like India……do you think it will not be of major interest to Davita…It will be of huge interest…Davita has over 1,000 dialysis centers nation wide
They are a perfect Hep C partner…….They will quickly see preliminary results.
Some consider ebola a flash in the pan…..treating Hep C patients is huge & there are tens of millions worldwide
My compass tells me this is J J's direction & current BIG INTEREST,……Effectibe Hep C treatment could mean billions of reoccurring dollars to davita & aemd
You get good Houston Hep C data and then the A F & his short buddies if still around will be toast
only mho B"
Recent AEMD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2024 10:15:18 PM
- Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update • PR Newswire (US) • 11/13/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 02:00:08 PM
- Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia • PR Newswire (US) • 11/11/2024 01:01:00 PM
- Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024 • PR Newswire (US) • 11/06/2024 01:01:00 PM
- Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit • PR Newswire (US) • 10/08/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 08:44:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 12:01:08 PM
- Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India • PR Newswire (US) • 09/19/2024 12:01:00 PM
- Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial • PR Newswire (US) • 09/16/2024 12:01:00 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum September 19th • GlobeNewswire Inc. • 09/13/2024 12:35:00 PM
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys • PR Newswire (US) • 08/27/2024 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:34:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/15/2024 08:32:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:30:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:01:08 PM
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 08/12/2024 12:01:00 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM